Clinical Trial Budget Management Software: 6 Tools and What They Miss

Ask a site director whether their last study came in on budget and you will usually get a confident yes. Ask whether it made money and the answer gets slower. Those are different questions, and most research organizations have software that answers the first one and nothing at all that answers the second.

Clinical trial budget software is a real, well-built category – price the protocol, benchmark the per patient cost, negotiate with the sponsor. This guide picks the best tools in that category, compares what each one actually does, and is honest about the half of the job none of them cover: watching what the study actually spends once it is running.

If you are choosing systems for a wider research stack rather than budgeting specifically, we have also mapped eleven categories of clinical trial software and the best tool in each.

What a clinical trial budget actually contains

A trial budget has three layers, and confusing them is where the trouble starts.

Per patient costs. Everything that happens because a participant walked through the door: study visits, procedures, labs, imaging, stipends, travel reimbursement. These are the numbers sponsors negotiate hardest, and they scale with enrollment.

Fixed and overhead costs. Ethics committee and IRB fees, pharmacy setup, archiving, equipment, and the institutional overhead rate applied on top. They happen whether you enroll two participants or two hundred.

Staff time. Coordinator hours, investigator time, regulatory work, monitoring visit support, data entry, query resolution. This layer is the largest cost at most sites, and it is the one usually captured as a vague administrative percentage instead of a measured quantity.

The first two layers are countable in advance, which is exactly what the software in this guide is built to do well. The third is a guess until the study is over, which is precisely why studies that look profitable on paper often are not.

What to look for before you buy

Every tool in this category is built around fair market value, or FMV – a benchmark figure meant to show that investigator compensation reflects genuine market rates rather than an amount inflated as an inducement to enroll patients faster. That is not a compliance nicety. The Anti-Kickback Statute’s safe harbor and the Stark Law’s compensation exceptions both require personal-service payments, which is what an investigator grant legally is, to be consistent with fair market value and never tied to referral or enrollment volume. An FMV number without a cited benchmark source and a written rationale behind it is exactly what an auditor looks for.

Vendors build that number two ways. A market based approach benchmarks against real negotiated grant data from past studies; a cost based approach builds the figure up from its component parts. Most platforms blend both, but the market based approach is only as good as the dataset behind it, which is why the size and freshness of a vendor’s benchmark data matters more here than almost any other feature.

Beyond FMV data, four questions separate these tools in practice:

• How much of the budget does it build automatically? Some tools still start from a template a human fills in. Others extract line items directly from an uploaded protocol and propose a first draft.
• Does it model amendments, or just the original protocol? A protocol change should trigger a cost recalculation, not a manual rebuild. Ask to see this specifically, since it is the feature most often claimed and least often demonstrated well.
• Does budgeting connect to site payments, or stop at the number? A budget that cannot execute payment against itself still needs a second system, which is the same gap this guide raises about tracking actual spend.
• Is the vendor’s own business stable? This category has consolidated fast – Suvoda and Greenphire merged in 2025 – and a platform mid-acquisition can mean roadmap uncertainty right when you are depending on it.

One more honest point before the comparison: a full enterprise FMV platform is built for sponsors and CROs running a real portfolio of studies. A single academic site, or a sponsor running one or two trials a year, often gets more value from a lighter benchmarking service or a consultant than from the deepest dataset on the market – the platforms below assume you have enough budgets to benchmark that the dataset is worth paying for.

The 7 options at a glance

Best clinical trial budget software

1. IQVIA CTFS GrantPlan

Key features:

• AI extraction of budget line items directly from an uploaded protocol
• Fair market value benchmarking across 175+ countries
• Historical site agreement visibility
• GPI (Investigator-Initiated Study) tools with FTE and specialty-based coding

GrantPlan is the scale option. IQVIA reports more than 655,000 finalized budgets and 38 million negotiated data points behind its benchmarks, which is the largest dataset of its kind that any vendor in this list publishes, and the company states the product is used by 90 percent of top pharmaceutical companies. That reach traces back to DrugDev, which IQVIA acquired and folded into its wider Golden Number data initiative.

The automation worth noting is protocol ingestion: upload the protocol and the system proposes budget line items rather than starting from a blank template. For a sponsor running a large portfolio, that depth of benchmark data is the actual product; the interface is secondary to the dataset behind it.

Best for: large pharmaceutical companies and enterprise sponsors who value benchmark depth over simplicity. Alternatives: Medidata CTFM, Suvoda Budgeting and Benchmarking.

Pricing: not publicly disclosed – IQVIA requires a scoping consultation, and no pricing page exists.

Free trial: none. The sales process is demo-led from the first contact.

Pros:

• Largest benchmark dataset in this comparison – 655,000+ finalized budgets and 38 million negotiated data points across 60+ countries, by IQVIA’s own figures
• AI extraction turns an uploaded protocol into a first-draft budget automatically instead of a blank template
• Connects directly to IQVIA’s own site and participant payments modules, giving a negotiated budget a path to execution

Cons:

• No independent reviews found specifically for GrantPlan – IQVIA’s G2 presence covers sibling products, not this one
• That dataset depth is the entire value proposition; a sponsor negotiating only a handful of grants a year will not use enough of it to justify the fit

2. Medidata CTFM

Key features:

• Budgeting linked to real time site negotiation
• Forecasting that updates with enrollment and protocol changes
• Automated multi-currency site payments
• Site facing financial transparency portal

Clinical Trial Financial Management, sold partly under the Grants Manager module name, is built around a specific idea: a budget that was correct at sign off is routinely wrong six months later, so the forecast should move with the study instead of waiting for a formal amendment to catch up.

The real argument for CTFM is less the budgeting module alone and more what it connects to. If your trials already run on Medidata Rave for data capture, financial data sits inside the same ecosystem instead of a separate system that needs its own integration project.

Best for: sponsors already standardized on Medidata for data capture or study management. Alternatives: IQVIA CTFS GrantPlan, Suvoda Budgeting and Benchmarking.

Pricing: not publicly disclosed – Medidata does not publish a pricing page for CTFM; contact sales directly.

Free trial: none. Access starts with a demo request.

Pros:

• Site payments trigger directly off data entered in Rave in real time – a specific integration mechanic none of the other five tools describe
• Forecasts update automatically as enrollment and protocol changes land, instead of waiting for a formal amendment to catch up
• A UK NIHR partner quoted in Medidata’s own customer materials credits CTFM with improving budget precision by up to 80 percent – a vendor-published figure, not independently audited, but a specific claim rather than a vague one

Cons:

• No independent reviews specific to CTFM or Grants Manager exist – Medidata’s G2 presence covers the broader Rave platform, not this module
• Real value depends on already running Rave for data capture; outside that ecosystem the integration case weakens considerably

3. Suvoda Budgeting and Benchmarking

Key features:

• Spreadsheet style visit schedule builder
• Multi scenario budget modeling
• Direct site negotiation templates
• Connected site payments module

Suvoda’s benchmark data spans more than 70 countries and draws on more than 100 sponsors, 30 CROs, and 30,000 payees, refreshed quarterly. The visit schedule builder works like a spreadsheet a budget analyst would actually recognize, and because the same company runs a site payments module, a negotiated budget has a direct path to execution rather than a handoff to a different vendor.

One thing to factor into the decision: Suvoda and Greenphire completed a merger in 2025, which puts this budgeting tool and Greenphire’s payments products under the same corporate roof as of this year. A single vendor for budgeting and payments has real appeal, but any tool you pick mid-integration carries roadmap risk until the combined product line settles.

Best for: sponsors who want budgeting and payment execution from one now-unified vendor. Alternatives: IQVIA CTFS GrantPlan, Medidata CTFM.

Pricing: not publicly disclosed – no pricing page; Suvoda works exclusively through a demo request.

Free trial: none.

Pros:

• Benchmark dataset spans 100+ sponsors, 30+ CROs, and 30,000+ payees across 70+ countries, refreshed quarterly, by Suvoda’s own figures
• 250+ proprietary cost codes capture administrative and procedure costs that other vendors’ benchmarks leave out
• One login carries a negotiated budget through to site payment execution, now that Suvoda owns both products

Cons:

• No independent review data found for this specific module
• Mid-merger with Greenphire as of 2025, which carries real roadmap uncertainty until the combined product line settles

4. Trialytix Budgeting

Key features:

• Budget calculation from patient, site, and timeline parameters
• Scenario modeling for alternative study designs
• Automatic cost recalculation on protocol amendments
• Integration with a broader study controlling suite

Trialytix calculates a study budget from the parameters that actually drive cost – patient count, site count, timeline – rather than starting from a line item template, and it recalculates automatically when an amendment changes any of those inputs instead of forcing a manual rebuild.

The buyer base is broader than most of this list: Trialytix explicitly targets CROs and pharma and biotech sponsors, but also academic research institutions, a segment the enterprise-scale platforms above do not really court.

Best for: organizations that want budgeting folded into a wider study controlling suite, including academic research institutions. Alternatives: IQVIA CTFS GrantPlan, Strategikon Clinical Maestro.

Pricing: not publicly disclosed, and no pricing page on trialytix.io or on its Capterra listing.

Free trial: no functional product trial. A free product tour, a downloadable Excel budget template, and a self-serve ROI calculator are available, but the software itself still requires a sales demo.

Pros:

• Budget recalculates automatically when an amendment changes patient count, site count, or timeline, with no manual rebuild
• Serves CROs, pharma, and academic research institutions – a broader buyer base than the enterprise-only tools above actually court
• Vendor states a full budget proposal can be completed in under an hour once parameters are set

Cons:

• Trialytix’s own Capterra listing shows zero user reviews – no independent validation exists yet for this product
• Pricing is quote-only, same as every other tool in this category

5. Strategikon Clinical Maestro

Key features:

• AI powered budget building through the Portfolio module
• RFP and bid grid management through Source Plus
• Change order and earned value tracking through Lead
• Vendor and category management through Vision

Clinical Maestro is less a single budgeting tool than a suite for managing the whole outsourcing relationship, and the budgeting module is where it starts. Strategikon states its AI can build a budget in under an hour and claims its benchmarking typically reduces budgets by about 10 percent, with average savings around $300,000 per outsourced trial – vendor figures worth testing against your own numbers rather than taking at face value, but directionally consistent with what automated benchmarking is supposed to do.

The modules beyond budgeting, RFP management, change order tracking, vendor management, are aimed specifically at sponsors who outsource heavily to CROs and need to manage that relationship as a portfolio, not just negotiate one grant at a time.

Best for: sponsors managing multiple CRO relationships who need vendor management alongside budgeting. Alternatives: IQVIA CTFS GrantPlan, Cloudbyz CTFM.

Pricing: not publicly disclosed – a free consultation is the only stated path in, with no pricing page.

Free trial: none.

Pros:

• Broadest scope in this comparison – budgeting, RFP and bid-grid management, change-order tracking, and vendor management inside one connected suite
• Published case studies cite specific outcomes, including one claiming 2x faster RFP-to-final-budget turnaround and $800,000 saved on a named engagement – more detail than most competitors publish, though still a vendor-selected case rather than an independent audit
• AI budget building is claimed to produce a first draft in under an hour

Cons:

• Every performance figure – the roughly 10 percent average budget reduction, the roughly $300,000 average savings per outsourced trial, the case-study percentages – is vendor-published with no independent source to check it against, and no G2 or Capterra listing exists for this product
• No public pricing; the sales process runs through a consultation rather than a demo request

6. Cloudbyz CTFM

Key features:

• Budget forecasting, tracking, and reconciliation
• Investigator grant administration with configurable payment triggers
• Protocol amendment cost impact analysis
• Native integration with CTMS, EDC, and eTMF systems

Cloudbyz built its Clinical Trial Finance Management product natively on Salesforce, which matters mainly if your organization already runs other Salesforce-based systems and wants one platform underneath everything. The feature set covers the same ground as the enterprise tools above: forecasting, grant administration, amendment impact analysis, multi-currency handling.

What sets it apart is who it is built for. Cloudbyz explicitly positions CTFM at mid-sized biotech running three to fifteen concurrent studies, a segment too small to need IQVIA or Medidata’s scale and too complex for a spreadsheet.

Best for: mid-sized biotech sponsors who have outgrown spreadsheets but do not need enterprise-scale benchmark depth. Alternatives: Trialytix Budgeting, Strategikon Clinical Maestro.

Pricing: not publicly disclosed – “Request a Live Demo” is the only stated path in, with no pricing page.

Free trial: none.

Pros:

• Most explicit integration list in this comparison, with bi-directional connections named for Workday, SAP, Oracle, NetSuite, and Dynamics 365
• Built natively on Salesforce, which removes an integration project for organizations already running Salesforce-based systems
• Compliance stack stated outright – 21 CFR Part 11, GDPR, and HIPAA, with audit trail and e-signature support

Cons:

• Speed claims (70 to 80 percent faster budgeting, 60 to 70 percent faster payments) are vendor-asserted with no cited methodology
• No independent review coverage found for this module, and no public pricing

7. actiTIME

Key features:

• Clinical trial timesheets tracked by sponsor, protocol, and task
• Cost of Work, Billing Summary, and Profit/Loss reports per study
• Budget alerts at the sponsor, protocol, or task level
• Self-hosted option for data residency

actiTIME does not belong in the comparison above, and it would be dishonest to pretend otherwise: it does not build budgets, benchmark grants, or negotiate with sponsors, and it is not a regulated system of record. Every tool in this list prices a study before it runs. actiTIME is the only one that measures what the study actually cost once staff hours start being spent against it.

That gap matters for a second reason beyond tracking the current study: a site or sponsor that has never recorded time against a protocol has no real basis for the next budget negotiation either. Coordinator effort varies enough between studies that averaging it is risky, and the only way to replace a guess with a number is to have measured one on a comparable protocol already. actiTIME is what produces that history – the hours your team logs on this year’s studies become the evidence behind next year’s budget, which is a role none of the six tools above plays.

Three reports do the actual work: one totals staff expense against each protocol, one totals what came out billable, and a third lines them up side by side so a sponsor, protocol, or task shows a real margin instead of an assumed one. That margin figure is what answers the question this whole guide keeps circling back to – whether the budget a benchmark produced actually survived contact with the hours the study took.

See what each study really costs in staff hours, and which protocols are worth running again

Try Free

Best for: anyone who needs to know what a running study costs in staff time, independent of which budgeting tool built the original number. Alternatives: none of the six tools above do this; the closest substitute is a general-purpose time tracker without the cost of work and profitability reporting built for research billing.

Pricing: public, which is unusual in this market – free for up to 3 users; 1–40 users at $6/user/month billed annually; 41–200 users at $5/user/month billed annually; 200+ users at $1,250/month billed annually; self-hosted from $120/user as a one-time purchase.

Free trial: 30 days, full feature access, no credit card required.

Pros:

• The only tool in this comparison with public pricing and a self-serve trial – no sales call required to start
• Cost of Work, Billing Summary, and Profit/Loss reports turn logged hours into an actual margin figure, not just a total
• Self-hosted option available for academic centers with data residency requirements

Cons:

• Does not build, benchmark, or negotiate a budget – a genuinely different category from the six tools above, not a substitute for any of them
• No fair market value benchmarking or regulatory-compliance dataset; it measures what a study cost, not what it should have cost going in

If you run trials for sponsors, our guide on actiTIME for CRO operations covers the setup in more detail, and our piece on CRO operational challenges covers the rest.

The costs these tools don’t track

Certain work is real, consumes staff hours, and is either unbilled or billed at a rate that never covered it. Every experienced coordinator can list these from memory, and none of the six budgeting tools above see them once the study is running.

• Screening participants who never enroll
• Preparing for and hosting monitoring visits
• Resolving data queries months after a visit
• Protocol amendments and reconsenting
• Regulatory document upkeep between studies
• Chasing sponsors for payment

Screening is the clearest example, because the volume is far higher than most budgets assume. Data from the Tufts Center for the Study of Drug Development, reported in Applied Clinical Trials, put the overall average screen failure rate at 36.3 percent across therapeutic areas, up from 34.7 percent in 2012, and considerably higher in central nervous system studies.

In some settings it is far worse. A Tata Memorial Centre audit of 15 randomized studies, published in ecancermedicalscience in 2022, screened 7,481 patients and enrolled 3,666 of them. The other 3,815, which is 51.0 percent, were screen failures. That audit is a single oncology center in India and its rate should not be read as a global average, but it makes the shape of the problem concrete: for every participant who enrolled, a second one consumed coordinator time and produced no enrollment revenue.

If your budget reimburses screen failures at all, it usually reimburses a fraction of them at a fraction of the visit cost. The gap is absorbed by staff hours that nobody counted, which is the same gap the FMV benchmark at the front of this guide cannot see either – it prices the visit, not the hours around it.

How to choose

Start with how many budgets you actually negotiate in a year. A sponsor running a real portfolio gets genuine value from IQVIA or Medidata’s depth of benchmark data; a site or small sponsor negotiating one or two grants a year is paying for a dataset it will barely use, and often does better with a lighter tool or a consultant instead.

From there, match the vendor to how you already work. If you are standardized on Medidata for data capture, CTFM removes an integration project the others would add. If you outsource heavily to CROs, Strategikon’s vendor management modules solve a problem budgeting alone does not touch. If you are a mid-sized biotech running a handful of concurrent studies, Cloudbyz is built for that scale specifically rather than scaled down from an enterprise product.

Whichever budgeting tool you choose, assume it stops the moment the study starts running, because for all six of them, it does. Pair it with something that measures actual staff time against the protocol, or the number you negotiated will stay a guess about whether it held up.

Common mistakes

• Treating the FMV number as the whole budget. A benchmark prices the visit and the procedure. It does not price screening, query resolution, or the monitoring visit support that happens around them – organizations that stop at the FMV figure are budgeting for half the real cost.
• Accepting a benchmark with no documented rationale. A per visit rate that cannot be traced back to a cited data source and a written justification is exactly what an Anti-Kickback Statute or Stark Law audit looks for. The number being fair market value on average does not help if nobody can show the work.
• Buying enterprise benchmark depth you will not use. The largest datasets in this category exist because sponsors negotiate hundreds of grants a year. A site negotiating a handful gets little marginal value from 38 million data points over a smaller, cheaper dataset.
• Never recording time against a protocol, then wondering why every budget is a guess. Coordinator effort varies enough between studies that an unmeasured average is close to meaningless. The only fix is measuring hours on the studies you are already running, which is the one thing none of the six budgeting tools above do.

Time documentation and federal awards

If any part of your research is funded by a federal award, time records stop being a management preference and become a compliance requirement. Under 2 CFR 200.430, charges to federal awards for salaries and wages must be based on records that accurately reflect the work performed.

This is the domain of time and effort reporting, and it is worth being precise about where a time tracker fits. actiTIME produces the underlying records and the reports that summarize hours by project and person. Formal effort certification, where a principal investigator attests that the distribution of effort is reasonable, belongs in your research administration system. Use the two together. Do not expect either to be the other.

Frequently asked questions

What is clinical trial budget management?

It is the practice of building a study budget, negotiating it with the sponsor, and then tracking actual spend against it while the study runs. Most organizations do the first two well and the third badly, because the tools that build budgets are not the tools that record what the work cost.

What is the difference between a budget-construction tool and a CTMS?

Budget software prices the protocol before it starts, using benchmark and fair market value data to set per patient costs and support negotiation. A CTMS runs the study operationally and tracks visits, procedures, invoices, and payments. Neither one measures the staff hours consumed producing that work, or converts those hours into a cost.

Why do studies that look profitable lose money?

Because the largest cost at most sites is staff time, and staff time is usually entered into the budget as an estimate and never measured afterwards. Unreimbursed screening, monitoring visit support, and query resolution then consume hours that no line item covers. The revenue side is tracked precisely and the cost side is guessed.

Is fair market value benchmarking legally required, or just best practice?

Legally required, not merely advisable, through the Anti-Kickback Statute and Stark Law provisions this guide covers above – though neither law names clinical trials specifically, since investigator grants simply fall under their general personal-service payment rules. What satisfies an auditor in practice is narrower than most people assume: a named benchmark source, a dated rationale memo kept on file at the time the budget was negotiated, and a documented review whenever a negotiated rate lands outside that benchmark’s range. Most organizations have the number. Few keep the memo and the review trail, which is exactly where an audit finds the gap.

Which tool should we use for clinical trial cost management?

It depends which stage is failing you. If your budgets are unrealistic, look at clinical trial budget software with fair market value benchmarks, sized to how many grants you actually negotiate a year. If invoices and payments are the problem, that is a CTMS. If you cannot say what a study cost or whether it was profitable, you need time and cost tracking alongside both.

Getting started

Pick one active protocol and track hours against it for a quarter. Set a cost rate per person, create tasks for screening and monitoring support, and run the Profit/Loss report at the end. Most sites are surprised, and the surprise is the point, because the same number tells you what to charge for the next study.

The five-step setup guide covers the mechanics. On the signup page, the free tier (capped at 3 users, no time limit) works if your team stays under that cap; otherwise run the 30-day trial to test the full feature set first.